A Phase 1, Single-Center, Randomized, Single-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Effects of Oral Administration of Lu AA21004 20 mg on the Concentrations of Selected Neurotransmitters in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2013
At a glance
- Drugs Vortioxetine (Primary)
- Indications Anxiety disorders; Depressive disorders
- Focus Biomarker; Pharmacodynamics
- Sponsors Takeda Global Research and Development Center
- 02 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 02 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.